Medicine Press release

Eisai Co., Ltd. announced today that it has been recognized as the 2025 KENKO Investment for Health by Japan's Ministry of Economy, Trade, and Industry (METI) and the Tokyo Stock Exchange, for the first time as a company strategically carrying out efforts with regard to its employees' health from a management perspective.
More info..

NEC Corporation (NEC; TSE: 6701) has announced that it will partner with the Nagasaki University DEJIMA Infectious Disease Research Alliance (Director: Prof. Kouichi Morita) for a research and development (R&D) project with support from the Coalition for Epidemic Preparedness Innovations (CEPI).
More info..

Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. announced today that they will conclude their co-promotion based on the co-promotion agreement in Japan regarding the orally-administered antifungal agent NAILIN Capsules 100 mg (generic name: fosravuconazole) which is manufactured and marketed by Sato Pharmaceutical, as of March 31, 2025.
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that the Therapeutic Goods Administration (TGA) of Australia has confirmed the initial decision to decline the approval of humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody lecanemab (generic name) as a treatment for early Alzheimer's disease (AD) (mild cognitive impairment due to AD and mild AD dementia).
More info..

Eisai Co., Ltd. announced today the launch of the new nutritional drink "Chocola BB Nightwell" (designated quasi-drug product), a nutritional drink to help recovery from the accumulated fatigue of the day during sleep, on Monday, March 3.
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed its positive opinion by consensus for the anti-Abeta; monoclonal antibody lecanemab, adopted in November 2024.
More info..

Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions and continue to manufacture and market it in Japan, where it has been already launched.
More info..

Olympus Corporation of Asia Pacific Limited (Olympus APAC), the regional headquarters of Olympus Corporation in Asia and Oceania, today announced a milestone for its iTind(TM) device with expanded availability across major markets in the Asia-Pacific (APAC) region, a move in line with its commitment and purpose of making people's lives healthier, safer and more fulfilling.
More info..

Olympus Corporation of Asia Pacific Limited (Olympus APAC), the regional headquarters of Olympus Corporation in Asia and Oceania, today announced a milestone for its iTind(TM) device with expanded availability across major markets in the Asia-Pacific (APAC) region, a move in line with its commitment and purpose of making people's lives healthier, safer and more fulfilling.
More info..

More info..